AC
CRDF icon

AXQ Capital’s Cardiff Oncology CRDF Stock Holding History

AXQ Capital’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17K Buy
+13,110
New +$20.8K ﹤0.01% 952

Other funds holding CRDF

LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

AXQ Capital's CRDF Position: Q2 2026 in Review

AXQ Capital opened a new position in Cardiff Oncology (CRDF) in Q2 2026: 13,110 shares worth $17K. The stake represents ﹤0.01% of the portfolio and ranks #952 among its holdings.

105 funds tracked by Wall St. Rank hold CRDF as of Q2 2026.

  • AXQ Capital held 13,110 shares of Cardiff Oncology worth $17K as of Q2 2026.
  • Cardiff Oncology was a new AXQ Capital position in Q2 2026.
  • Cardiff Oncology made up ﹤0.01% of AXQ Capital's portfolio in Q2 2026, its #952 holding.
  • 105 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2026.

Based on AXQ Capital's 13F filing for Q2 2026, filed 6 Aug 2026.